← Back to Clinical Trials
RecruitingPhase 4NCT05669534

Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionHiv
SponsorUniversity of Connecticut
Study TypeINTERVENTIONAL
PhasePhase 4
Enrollment256
SexALL
Min Age18 Years
Max AgeN/A
Start Date2023-03-01
Completion2027-01
Interventions
community-friendly health recovery programPre-Exposure Prophylaxis and Post-Exposure Prophylaxis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The investigators will conduct an optimization trial among N=256 PWID newly started on medication for opioid use disorder and Pre-Exposure Prophylaxis (PrEP) to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize HIV prevention content, leading to improvements in HIV prevention information, motivation, behavioral skills, and behaviors (IMB).

Eligibility Criteria

Inclusion Criteria: * being 18 years or older * meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone, buprenorphine) at the APT Foundation, Inc. * showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening * having initiated Pre-Exposure Prophylaxis (PrEP) within the past week * confirming HIV-negative status through proof of PrEP prescription * reporting unsafe injection drug use practices or unprotected sex within the past 3 months * having a cell phone * being able to read and understand in English Exclusion Criteria: * unable to provide consent * actively suicidal * actively homicidal * actively psychotic * display MoCA scores suggestive of dementia

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology